计算溶液所需的质量、体积或浓度。
这是演示店铺,请务下单付款,避免造成你的财物损失。
为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
I412009-1mg (试用装) 申请此免费试用装(?) 作为尊贵的客户,您每年可免费申请一次试用装产品,尽享探索与享受!
|
1mg | 现货 | | |
I412009-5mg |
5mg | 现货 | | |
I412009-10mg |
10mg | 期货 | |
产品名称 | Infliximab (anti-TNF-alpha) |
---|---|
别名 | Infliximab; Remicade; Remsima; Inflectra; Avakine; CT-P13; 英夫利昔单抗; APC1 antibody; APC1 protein antibody; Cachectin antibody; DIF antibody; Differentiation inducing factor antibody; Macrophage cytotoxic factor antibody; Tnf antibody; TNF superfamily member |
英文别名 | Infliximab; Remicade; Remsima; Inflectra; Avakine; CT-P13; APC1 antibody; APC1 protein antibody; Cachectin antibody; DIF antibody; Differentiation inducing factor antibody; Macrophage cytotoxic factor antibody; Tnf antibody; TNF superfamily member 2 antib |
规格或纯度 | Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated |
特异性 | TNFSF2/TNFa |
应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
反应种属 | Cynomolgus,Human |
抗体类型 | Primary antibody |
---|---|
Format | Whole IgG |
亚型 | Human IgG1 |
轻链亚型 | Kappa |
SDS-PAGE | 27.6 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 186.7 kDa, under non-reducing conditions. |
纯化方法 | Protein A purified |
来源 | CHO supernatant |
物理外观 | Liquid |
储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-AC, 20mM Arg, pH 5.0 |
防腐剂 | No |
浓度 | Lot by Lot |
储存温度 | -80℃储存,避免反复冻融 |
运输条件 | 超低温冰袋运输 |
稳定性与储存 | Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
CAS编号和信息 | 170277-31-3 |
Wikipedia | Infliximab |
---|---|
IMGT/mAb-DB | 156 |
PubChem SID | 178101701 |
PEP | infliximab |
Immunopaedia Search | infliximab |
输入批号以搜索COA:
Infliximab (anti-TNF-alpha) (I412009) - ELISA
Immobilized Recombinant Human TNF-alpha Protein (rp156007) at 0.5 μg/mL can bind Infliximab (anti-TNF-alpha) (I412009) with the EC₅₀ of 31.52 ng/mL.
Infliximab (anti-TNF-alpha) (I412009) - SEC
The purity of Infliximab (anti-TNF-alpha) (I412009) is more than 95% verified by HPLC.
您好,该产品的储存缓冲液Pro-AC是指脯氨酸醋酸缓冲液。
1. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL et al.. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.. Gastroenterology, 117 (4): (761-9). [PMID:10500056] |
2. Blair HA, Deeks ED. (2016) Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.. BioDrugs, 30 (5): (469-480). [PMID:27650650] |
3. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B et al.. (2017) Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.. Ann Rheum Dis, 76 (2): (355-363). [PMID:27130908] |
4. Derzi M, Johnson TR, Shoieb AM, Conlon HD, Sharpe P, Saati A, Koob S, Bolt MW, Lorello LG, McNally J et al.. (2016) Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab).. Adv Ther, 33 (11): (1964-1982). [PMID:27585978] |
5. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).. Gastroenterology, 109 (1): (129-35). [PMID:7797011] |
6. A-González N, Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.. Biochim Biophys Acta, 1812 (8): (982-94). [PMID:21193033] |